

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6453190

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Execution Date
MIDCAP FINANCIAL TRUST, AS AGENT	12/07/2020

**RECEIVING PARTY DATA**

<b>Name:</b>	BIOCRIST PHARMACEUTICALS, INC.
<b>Street Address:</b>	4505 EMPEROR BLVD., SUITE 200
<b>City:</b>	DURHAM
<b>State/Country:</b>	NORTH CAROLINA
<b>Postal Code:</b>	27703
<b>Name:</b>	MDCP, LLC
<b>Street Address:</b>	4505 EMPEROR BLVD, SUITE 200
<b>City:</b>	DURHAM
<b>State/Country:</b>	NORTH CAROLINA
<b>Postal Code:</b>	27703

**PROPERTY NUMBERS Total: 70**

Property Type	Number
Patent Number:	6562861
Patent Number:	8778997
Patent Number:	6503745
Patent Number:	6576786
Patent Number:	6495711
Patent Number:	6762316
Patent Number:	6410594
Patent Number:	6509359
Patent Number:	6518299
Patent Number:	5985848
Patent Number:	6066722
Patent Number:	6492347
Patent Number:	6803455
Patent Number:	7211653
Patent Number:	7390890

PATENT

<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	6693193
<b>Patent Number:</b>	7022852
<b>Patent Number:</b>	7211677
<b>Patent Number:</b>	7405297
<b>Patent Number:</b>	7553839
<b>Patent Number:</b>	8173662
<b>Patent Number:</b>	8501753
<b>Patent Number:</b>	8853224
<b>Patent Number:</b>	6656915
<b>Patent Number:</b>	6660719
<b>Patent Number:</b>	7230119
<b>Patent Number:</b>	6972331
<b>Patent Number:</b>	6946554
<b>Patent Number:</b>	6458799
<b>Patent Number:</b>	6780993
<b>Patent Number:</b>	8440813
<b>Patent Number:</b>	7429571
<b>Patent Number:</b>	7514410
<b>Patent Number:</b>	8163703
<b>Patent Number:</b>	7388002
<b>Patent Number:</b>	8242085
<b>Patent Number:</b>	7560434
<b>Patent Number:</b>	6653340
<b>Patent Number:</b>	6699994
<b>Patent Number:</b>	6936719
<b>Patent Number:</b>	9770427
<b>Patent Number:</b>	6228847
<b>Patent Number:</b>	8344132
<b>Patent Number:</b>	9492452
<b>Patent Number:</b>	10022375
<b>Patent Number:</b>	9580428
<b>Patent Number:</b>	10125102
<b>Patent Number:</b>	9499554
<b>Application Number:</b>	14313738
<b>Application Number:</b>	14190987
<b>Application Number:</b>	13879110
<b>Application Number:</b>	14531471
<b>Application Number:</b>	14441762

Property Type	Number
Application Number:	14395355
Application Number:	14890719
Application Number:	15123059
Application Number:	15337320
Application Number:	15714918
Application Number:	16013059
Application Number:	15505534
Application Number:	15977129
Application Number:	16009943
Application Number:	15764071
Application Number:	16073934
Application Number:	16082437
PCT Number:	US2015046578
PCT Number:	US2016048456
PCT Number:	US2015046582
PCT Number:	US2017058685
PCT Number:	US2018037503

**CORRESPONDENCE DATA**

**Fax Number:** (617)371-1037  
*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 617-371-1003  
**Email:** catherine.heath@hoganlovells.com  
**Correspondent Name:** KRISTIN A. CONNARN  
**Address Line 1:** HOGAN LOVELLS US LLP  
**Address Line 2:** 125 HIGH STREET, SUITE 2101  
**Address Line 4:** BOSTON, MASSACHUSETTS 02110

<b>ATTORNEY DOCKET NUMBER:</b>	041613.000029
<b>NAME OF SUBMITTER:</b>	KRISTIN A. CONNARN
<b>SIGNATURE:</b>	/Kristin A. Connarn/
<b>DATE SIGNED:</b>	12/16/2020

**Total Attachments: 10**  
source=ReleaseofSecurityInterest#page1.tif  
source=ReleaseofSecurityInterest#page2.tif  
source=ReleaseofSecurityInterest#page3.tif  
source=ReleaseofSecurityInterest#page4.tif  
source=ReleaseofSecurityInterest#page5.tif  
source=ReleaseofSecurityInterest#page6.tif  
source=ReleaseofSecurityInterest#page7.tif  
source=ReleaseofSecurityInterest#page8.tif

source=ReleaseofSecurityInterest#page9.tif  
source=ReleaseofSecurityInterest#page10.tif

**RELEASE OF SECURITY INTEREST  
IN INTELLECTUAL PROPERTY**

This Release of Security Interest in Intellectual Property, dated as of December 7, 2020, is made by **MIDCAP FINANCIAL TRUST**, a Delaware statutory trust, (“**Agent**”), in favor of **BIOCRIST PHARMACEUTICALS, INC.**, a Delaware corporation (“**Biocryst**”) and **MDCP, LLC**, a Delaware limited liability company (“**MDCP**” and together with Biocryst, the “**Grantors**” and each, a “**Grantor**”):

WHEREAS, pursuant to that certain Intellectual Property Security Agreement, dated as of September 23, 2016 (as may have been further amended, modified, restated, replaced or supplemented from time to time, the “**IP Security Agreement**”; capitalized terms used herein have the definition provided for in the IP Security Agreement), recorded with the United States Patent and Trademark Office on August 9, 2018 at Reel/Frame No. 6408/0819 (Trademarks) and on August 9, 2018 at Reel/Frame No. 046599/0580 (Patents), each Grantor granted Agent, on behalf of the Lenders, a security interest in and to all of its right, title and interest in all of such Grantor’s intellectual property, including those listed on Exhibits A through D thereto;

WHEREAS, the Grantors have requested that Agent release its security interest in and to the patent assets as more particularly described on Schedule A attached hereto (the “**Released Patents**”).

WHEREAS, the Grantors have requested that Agent release its security interest in and to the trademark assets as more particularly described on Schedule B attached hereto (the “**Released Trademarks**”).

WHEREAS, the Grantors have requested that Agent release its security interest in and to the various intellectual property assets set forth in Sections (a) through (j) of the IP Security Agreement (together with the Released Patents and Released Trademarks, the “**Released IP Collateral**”).

NOW, THEREFORE, Agent, without recourse, representation or warranty and at Grantors’ sole cost and expense, hereby releases all of its right, title and interest in and to the Released IP Collateral.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Agent has caused this Release of Security Interest in Intellectual Property to be duly executed and delivered by its duly authorized officer as of the date first written above.

**AGENT:**

**MIDCAP FINANCIAL TRUST**

as Agent

By: Apollo Capital Management, L.P.,  
its investment manager

By: Apollo Capital Management GP, LLC,  
its general partner

By:   
\_\_\_\_\_

Name: Maurice Amsellem

Title: Authorized Signatory

Schedule A

Patents

*(See attached)*

**EXHIBIT B**  
**Summary of US Patents and Applications in BioCryst Patent Estate - September 14, 2016**

<b>Borrower that is Owner of IP<sup>1</sup></b>	<b>Name/Identifier of IP</b>	<b>Type of IP</b>	<b>Patent or Application Number</b>	<b>Filing Date<sup>2</sup></b>	<b>Projected Expiration Date<sup>3</sup></b>
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Patent	6,562,861	12/17/1998	12/17/2018
BioCryst	Antiviral Treatments	Patent	8,778,997	02/12/2007*	05/07/2027
BioCryst	Antiviral Treatments	Patent	14,313,738	02/12/2007*	02/12/2027
BioCryst	Cyclopentane and Cyclopentene Compounds and Use for Detecting Influenza Virus	Patent	6,503,745	11/05/1999	11/05/2019
BioCryst	Process for Preparing Substituted Cyclopentane Derivatives and Novel Crystalline Structures Thereof	Patent	6,576,786	06/09/2000*	06/09/2020
BioCryst	Process for Preparing (-)-(1S,4R) N-Protected 4-Amino-2-Cyclopentene-1-Carboxylate Esters	Patent	6,495,711	06/09/2000*	06/09/2020
BioCryst	Preparation of Substituted Cyclopentane and Cyclopentene Compounds and Certain Intermediates	Patent	6,762,316	06/28/2000	06/28/2020
BioCryst	Substituted Cyclopentane Compounds Useful as Neuraminidase Inhibitors	Patent	6,410,594	06/13/1997	06/13/2017
BioCryst	Pyrrolidin-2-One Compounds and Their Use as Neuraminidase Inhibitors	Patent	6,509,359	09/17/1998	09/17/2018
BioCryst	Substituted Pyrrolidine Compounds Useful as Neuraminidase Inhibitors	Patent	6,518,299	10/20/2000*	10/20/2020
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	5,985,848	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	6,066,722	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	6,228,847	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	6,492,347	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	6,803,455	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	7,211,653	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	7,390,890	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	6,693,193	04/07/2000	04/07/2020
BioCryst*	Process for Preparing 2-Pyrrolidinyl-1H- Pyrrolo[3,2-d] Pyrimidine Inhibitors of Nucleoside Metabolism	Patent			

*Confidential*



**EXHIBIT B**

**Summary of US Patents and Applications in BioCryst Patent Estate - September 14, 2016**

<b>Borrower that is Owner of IP<sup>1</sup></b>	<b>Name/Identifier of IP</b>	<b>Type of IP</b>	<b>Patent or Application Number</b>	<b>Filing Date<sup>2</sup></b>	<b>Projected Expiration Date<sup>3</sup></b>
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	7,022,852	04/07/2000	08/16/2020
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	7,211,677	04/07/2000	04/07/2020
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	7,405,297	04/07/2000	04/07/2020
BioCryst	Methods of Treating Hematologic Cancers	Patent	14/190,987	12/10/2008	12/10/2028
BioCryst*	5H-Pyrrolo[3,2-d] Pyrimidine Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Patent	7,553,839	08/21/2003	12/03/2023
BioCryst*	Fused Pyrimidines as Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Patent	8,173,662	08/21/2003	09/01/2024
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-Ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	Patent	8,501,753	03/24/2010	03/24/2030
BioCryst*	Acyclic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Patent	8,853,224	09/07/2007	03/29/2029
BioCryst	Inhibiting T-Cell Proliferation	Patent	6,656,915	09/15/2000	09/15/2020
BioCryst	Inhibiting T-Cell Proliferation	Patent	6,660,719	12/17/2001*	02/10/2022
BioCryst	Process for the Preparation of Substituted Pyrrolidine Derivatives and Intermediates	Patent	7,230,119	08/25/2005*	10/10/2025
BioCryst	Carboxy Pyrrole, Process of Preparing and Use as Precursor	Patent	6,972,331	04/23/2003*	12/20/2023
BioCryst	Process for the Preparation of 9-Deazaguanine Derivatives	Patent	6,946,554	12/10/1996*	12/10/2016
BioCryst	Deazaguanine Analog, Preparation Thereof and Use Thereof	Patent	6,458,799	05/04/2001*	05/04/2021
BioCryst	Preparation of Deazaguanine Analog	Patent	6,780,993	02/19/2003*	02/19/2023
BioCryst	Antiviral Nucleoside Analogs	Patent	8,440,813	01/11/2008	11/16/2028
BioCryst	Therapeutic Furoprimidines and Thienopyrimidines	Patent	7,429,571	10/28/2005	07/17/2026

*Confidential*

**EXHIBIT B**  
**Summary of US Patents and Applications in BioCryst Patent Estate - September 14, 2016**

<b>Borrower that is Owner of IP<sup>1</sup></b>	<b>Name/Identifier of IP</b>	<b>Type of IP</b>	<b>Patent or Application Number</b>	<b>Filing Date<sup>2</sup></b>	<b>Projected Expiration Date<sup>3</sup></b>
BioCryst	Methods for the Preparation of 9-Deazapurine Derivatives	Patent	8,344,132	06/21/2006	03/28/2028
BioCryst	Hepatitis C Therapies	Patent	7,514,410	10/28/2005	10/14/2026
BioCryst	Hepatitis C Therapies	Patent	8,163,703	10/28/2005	10/14/2026
BioCryst	Nucleosides, Preparation Thereof and Use as Inhibitors of RNA Viral Polymerases	Patent	7,388,002	11/14/2002	12/31/2022
BioCryst	Tetrahydrofuro [3 4-D] Dioxolane Compounds for Use in the Treatment of Viral Infections and Cancer	Patent	8,242,085	05/08/2008	11/16/2028
BioCryst	Aza Nucleosides, Preparation Thereof and Use as Inhibitors of RNA Viral Polymerases	Patent	7,560,434	06/22/2005*	08/06/2026
BioCryst	Methods and Compositions for Inhibition of Polymerase	Patent	13/879,110	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Patent	14/531,471	10/14/2011	10/14/2031
BioCryst	Antiviral Azasugar-containing Nucleosides	Patent	14/441,762	11/18/2013	11/18/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Patent	14/395,355	04/17/2013	04/17/2033
BioCryst	Anti-Influenza Compositions and Methods	Patent	14/890,719	05/14/2014	05/14/2034
BioCryst	Compounds Useful in the Complement, Coagulat (sic) and Kallikrein Pathways and Methods for Their Preparation	Patent	6,653,340	06/03/1998	06/03/2018
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Patent	6,699,994	10/22/2001	11/09/2021
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Patent	6,936,719	10/22/2001	11/09/2021
BioCryst	Compositions and Uses of Amidine Derivatives	Patent	PCT/US2015/046578	08/24/2015	08/24/2035
BioCryst	Compositions Comprising a Kallikrein Inhibitor	Patent	PCT/US2016/048456 <sup>4</sup>	08/24/2016	08/24/2036
BioCryst	Method for Producing Amidine Derivatives	Patent	PCT/US2015/046582	08/24/2015	08/24/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Patent	15/123,059 <sup>5</sup>	03/09/2015	03/09/2035

*Confidential*

Summary of US Patents and Applications in BioCryst Patent Estate – January 17, 2019

Borrower that is Owner of IP <sup>1</sup>	Name/Identifier of IP	Type of IP	Patent or Application Number	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Patent	6,562,861	12/17/1998	12/17/2019
BioCryst	Antiviral Treatments	Patent	8,778,997	02/12/2007*	05/07/2027
BioCryst	Antiviral Treatments	Patent	9,770,427 (14/313,738)	02/12/2007*	02/12/2027
BioCryst	Antiviral Treatments	Patent	15/714,918 <sup>4</sup>	02/12/2007*	02/12/2027
BioCryst	Cyclopentane and Cyclopentene Compounds and Use for Detecting Influenza Virus	Patent	6,503,745	11/05/1999	11/05/2019
BioCryst	Process for Preparing Substituted Cyclopentane Derivatives and Novel Crystalline Structures Thereof	Patent	6,576,786	06/09/2000*	06/09/2020
BioCryst	Process for Preparing (-)-(1S,4R) N-Protected 4-Amino-2-Cyclopentene-1-Carboxylate Esters	Patent	6,495,711	06/09/2000*	06/09/2020
BioCryst	Preparation of Substituted Cyclopentane and Cyclopentene Compounds and Certain Intermediates	Patent	6,762,316	06/28/2000	06/28/2020
BioCryst	Substituted Cyclopentane Compounds Useful as Neuraminidase Inhibitors	Patent	6,410,594	06/13/1997	06/13/2017
BioCryst	Pyrrolidin-2-One Compounds and Their Use as Neuraminidase Inhibitors	Patent	6,509,359	09/17/1998	09/17/2018
BioCryst	Substituted Pyrrolidine Compounds Useful as Neuraminidase Inhibitors	Patent	6,518,299	10/20/2000*	10/20/2020
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	5,985,848	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	6,066,722	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	6,228,847	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	6,492,347	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	6,803,455	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	7,211,653	10/14/1997*	10/14/2017
BioCryst*	Inhibitors of Nucleoside Metabolism	Patent	7,390,890	10/14/1997*	10/14/2017
BioCryst*	Process for Preparing 2-Pyrrolidinyl-1H-Pyrrolo[3,2-d] Pyrimidine Inhibitors of	Patent	6,693,193	04/07/2000	04/07/2020

Summary of US Patents and Applications in BioCryst Patent Estate – January 17, 2019

Borrower that is Owner of IP <sup>1</sup>	Name/Identifier of IP	Type of IP	Patent or Application Number	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
	Nucleoside Metabolism				
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	7,022,852	04/07/2000	08/16/2020
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	7,211,677	04/07/2000	04/07/2020
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Patent	7,405,297	04/07/2000	04/07/2020
BioCryst	Methods of Treating Hematologic Cancers	Patent	14,190,987	12/10/2008	12/10/2028
BioCryst*	5H-Pyrrolo[3,2-d] Pyrimidine Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Patent	7,553,839	08/21/2003	12/03/2023
BioCryst*	Fused Pyrimidines as Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Patent	8,173,662	08/21/2003	09/01/2024
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	Patent	8,501,753	03/24/2010	03/24/2030
BioCryst*	Acyclic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Patent	8,853,224	09/07/2007	03/29/2029
BioCryst	Inhibiting T-Cell Proliferation	Patent	6,656,915	09/15/2000	09/15/2020
BioCryst	Inhibiting T-Cell Proliferation	Patent	6,660,719	12/17/2001*	02/10/2022
BioCryst	Process for the Preparation of Substituted Pyrrolidine Derivatives and Intermediates	Patent	7,230,119	08/25/2005*	10/10/2025
BioCryst	Carboxy Pyrrole, Process of Preparing and Use as Precursor	Patent	6,972,331	04/23/2003*	12/20/2023
BioCryst	Process for the Preparation of 9-Deazaguanine Derivatives	Patent	6,946,554	12/10/1996*	12/10/2016
BioCryst	Deazaguanine Analog, Preparation Thereof and Use Thereof	Patent	6,458,799	05/04/2001*	05/04/2021
BioCryst	Preparation of Deazaguanine Analog	Patent	6,780,993	02/19/2003*	02/19/2023
BioCryst	Antiviral Nucleoside Analogs	Patent	8,440,813	01/11/2008	11/16/2028
BioCryst	Therapeutic Furopyrimidines and	Patent	7,429,571	10/28/2005	07/17/2026

Summary of US Patents and Applications in BioCryst Patent Estate – January 17, 2019

Borrower that is Owner of IP <sup>1</sup>	Name/Identifier of IP	Type of IP	Patent or Application Number	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
	Thienopyrimidines				
BioCryst	Methods for the Preparation of 9-Deazapurine Derivatives	Patent	8,344,132	06/21/2006	03/28/2028
BioCryst	Hepatitis C Therapies	Patent	7,514,410	10/28/2005	10/14/2026
BioCryst	Hepatitis C Therapies	Patent	8,163,703	10/28/2005	10/14/2026
BioCryst	Nucleosides, Preparation Thereof and Use as Inhibitors of RNA Viral Polymerases	Patent	7,388,002	11/14/2002	12/31/2022
BioCryst	Tetrahydrofuro [3 4-D] Dioxolane Compounds for Use in the Treatment of Viral Infections and Cancer	Patent	8,242,085	05/08/2008	11/16/2028
BioCryst	Aza Nucleosides, Preparation Thereof and Use as Inhibitors of RNA Viral Polymerases	Patent	7,560,434	06/22/2005*	08/06/2026
BioCryst	Methods and Compositions for Inhibition of Polymerase	Patent	9,492,452 (14/531,471)	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Patent	10,022,375 (15/337,320) <sup>5</sup>	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Patent	16/013,059 <sup>6</sup>	10/14/2011	10/14/2031
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Patent	9,580,428 (14/395,355)	04/17/2013	04/17/2033
BioCryst	Anti-Influenza Compositions and Methods	Patent	9,499,554 (14/890,719)	05/14/2014	05/14/2034
BioCryst	Compounds Useful in the Complement, Coagulation ( <i>sic</i> ) and Kallikrein Pathways and Methods for Their Preparation	Patent	6,653,340	06/03/1998	06/03/2018
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Patent	6,699,994	10/22/2001	11/09/2021
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Patent	6,936,719	10/22/2001	11/09/2021
BioCryst	Compositions and Uses of Amidine Derivatives	Patent	15/505,534 <sup>7</sup>	08/24/2015	08/24/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Patent	10,125,102 (15/123,059) <sup>8</sup>	03/09/2015	03/09/2035

Summary of US Patents and Applications in BioCryst Patent Estate – January 17, 2019

Borrower that is Owner of IP <sup>1</sup>	Name/Identifier of IP	Type of IP	Patent or Application Number	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
BioCryst	Human Plasma Kallikrein Inhibitors	Patent	15/977,129 <sup>9</sup>	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Patent	16/009,943 <sup>10</sup>	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Patent	15/764,071 <sup>11</sup>	09/30/2016	09/30/2036
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Patent	16/073,934 <sup>12</sup>	02/01/2017	02/01/2037
BioCryst	Methods and Compositions for Treatment of Zika Virus Infection	Patent	16/082,437 <sup>13</sup>	03/06/2017	03/06/2037
BioCryst	Prodrugs of Kallikrein Inhibitors	Patent	PCT/US2017/058685	10/27/2017	10/27/2037
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Patent	PCT/US2018/037503	06/14/2018	06/14/2038

NOTES:

- <sup>1</sup> The asterisk (\*) indicates "Licensee" status.
- <sup>2</sup> Unless otherwise indicated, PCT filing date is listed. The asterisk (\*) indicates earliest US Utility filing date for non-PCT- based applications.
- <sup>3</sup> Projected expiration dates extending beyond 20 years include PTA or PTE adjustments.
- <sup>4</sup> Safety continuation application based on parent US 14/313,738.
- <sup>5</sup> Safety continuation application based on parent US 14/531,471.
- <sup>6</sup> Safety continuation application based on parent US 15/337,320.
- <sup>7</sup> US national-stage of PCT/US2015/046578.
- <sup>8</sup> US national-stage of PCT/US2015/019535.
- <sup>9</sup> Safety continuation application based on parent US 15/123,059.
- <sup>10</sup> Safety divisional application based on parent US 15/123,059.
- <sup>11</sup> US national-stage of PCT/US2016/054619.
- <sup>12</sup> US national-stage of PCT/US2017/015953.
- <sup>13</sup> US national-stage of PCT/US2017/020961.